Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of type 2 diabetes mellitus~* Must have inadequate diabetes control (as defined by glycosylated hemoglobin level \>=7.0% to \<=10.5% at screening)~* Greater than or equal to (\>=) 30 yrs old with history of cardiovascular (CV) event, or \>= 50 yrs old with high risk of CV events~* Must be either not on antihyperglycemic agents (AHA) therapy, or on AHA monotherapy, or combination AHA therapy with any approved agent for the control of blood glucose levels.~Exclusion Criteria~* History of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* History of one or more severe hypoglycemic episode within 6 months before screening~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Ongoing, inadequately controlled thyroid disorder~* Renal disease that required treatment with immunosuppressive therapy or a history of chronic dialysis or renal transplant~* Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 3 months before screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (JNJ-28431754) (Type: EXPERIMENTAL): Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive placebo (inactive medication) once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).